Terms: = Pancreatic cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
239 results:
1. The Effect of Intratumor Heterogeneity in pancreatic Ductal Adenocarcinoma Progression and treatment.
Saleh O; Shihadeh H; Yousef A; Erekat H; Abdallh F; Al-Leimon A; Elsalhy R; Altiti A; Dajani M; AlBarakat MM
Pancreas; 2024 May; 53(5):e450-e465. PubMed ID: 38728212
[TBL] [Abstract] [Full Text] [Related]
2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant k-ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
3. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
[TBL] [Abstract] [Full Text] [Related]
4. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
5. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer.
Rowell MC; Deschênes-Simard X; Lopes-Paciencia S; Le Calvé B; Kalegari P; Mignacca L; Fernandez-Ruiz A; Guillon J; Lessard F; Bourdeau V; Igelmann S; Duman AM; Stanom Y; Kottakis F; Deshpande V; Krizhanovsky V; Bardeesy N; Ferbeyre G
Cell Cycle; 2023 Oct; 22(19):2172-2193. PubMed ID: 37942963
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer.
Briseño-Díaz P; Schnoor M; Bello-Ramirez M; Correa-Basurto J; Rojo-Domínguez A; Arregui L; Vega L; Núñez-González E; Palau-Hernández LA; Parra-Torres CG; García Córdova OM; Zepeda-Castilla E; Torices-Escalante E; Domínguez-Camacho L; Xoconostle-Cazares B; Meraz-Ríos MA; Delfín-Azuara S; Carrión-Estrada DA; Villegas-Sepúlveda N; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813486
[TBL] [Abstract] [Full Text] [Related]
7. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
8. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
9. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
[TBL] [Abstract] [Full Text] [Related]
10. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
11. A comprehensive review of pancreatic cancer and its therapeutic challenges.
Jiang S; Fagman JB; Ma Y; Liu J; Vihav C; Engstrom C; Liu B; Chen C
Aging (Albany NY); 2022 Sep; 14(18):7635-7649. PubMed ID: 36173644
[TBL] [Abstract] [Full Text] [Related]
12. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in k-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
13. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
14. Targeting G-Quadruplex DNA for cancer Chemotherapy.
Debbarma S; Acharya PC
Curr Drug Discov Technol; 2022; 19(3):e140222201110. PubMed ID: 35156574
[TBL] [Abstract] [Full Text] [Related]
15. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract] [Full Text] [Related]
16. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
17. Recent Advances in pancreatic cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract] [Full Text] [Related]
18. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract] [Full Text] [Related]
19. treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract] [Full Text] [Related]
20. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
[Next]